Aerospace Group:

Homeland Security

DoD Awards Morphotek $2.3M to Develop Biowarfare Therapies

DDN

Wednesday, October 3rd, 2007

SHARE:

Morphotek, Inc., a subsidiary of Japanese pharmaceutical company Eisai Co., received $2.3 million in funding from the Department of Defense to support the development of biologic- based monoclonal antibody therapies against biowarfare agents. Under the nine-month contract Morphotek will continue developing the therapies to treat Botulinum neurotoxins. "The further development of these compounds will enable us to advance these leads into clinical studies for validation and registration," says Nicholas Nicolaides, president and CEO of Morphotek.

Space

Upgrading Current GPS Ground System “Now a Viable Option,” As GPS OCX Problems Continue, Space Official Says

Upgrades to the GPS ground system–the Architecture Evolution Plan (AEP)–is an option under consideration by the Defense Department’s space acquisition chief, as problems continue in fielding the GPS Next Generation […]

Congress

Graham Says GOP To Move Ahead On Second Reconciliation Bill, With Defense Funds As Priority

Senate Budget Committee Chair Lindsey Graham (R-S.C.) said Wednesday, with the White House’s backing, his panel will move “expeditiously” on crafting a second reconciliation bill, citing priorities for defense and […]

Pentagon

Hegseth Acknowledges Potential $200 Billion Iran Supplemental Request, Final Figure ‘Could Move’

Defense Secretary Pete Hegseth on Thursday acknowledged the Pentagon could potentially ask Congress for $200 billion in supplemental funding to support the ongoing operation against Iran and replenish munitions used […]

Congress

Counter-Drone Flyaway Kit Used In U.S. In Early Hours Of Iran Strikes, NORTHCOM Head Says

U.S. Northern Command (NORTHCOM) used a counter small unmanned aircraft system (sUAS) flyaway kit (FAK) in the early hours of the strikes against Iran on Feb. 28, according to Air […]